![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SDC2 |
Gene summary for SDC2 |
![]() |
Gene information | Species | Human | Gene symbol | SDC2 | Gene ID | 6383 |
Gene name | syndecan 2 | |
Gene Alias | CD362 | |
Cytomap | 8q22.1 | |
Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | A0A024R9D1 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6383 | SDC2 | GSM4909281 | Human | Breast | IDC | 8.25e-55 | 9.48e-01 | 0.21 |
6383 | SDC2 | GSM4909282 | Human | Breast | IDC | 4.15e-04 | 1.79e-01 | -0.0288 |
6383 | SDC2 | GSM4909285 | Human | Breast | IDC | 5.05e-04 | 1.34e-01 | 0.21 |
6383 | SDC2 | GSM4909295 | Human | Breast | IDC | 3.30e-06 | 4.16e-01 | 0.0898 |
6383 | SDC2 | GSM4909299 | Human | Breast | IDC | 7.12e-13 | 4.31e-01 | 0.035 |
6383 | SDC2 | GSM4909305 | Human | Breast | IDC | 2.71e-08 | 3.94e-01 | 0.0436 |
6383 | SDC2 | GSM4909313 | Human | Breast | IDC | 4.74e-02 | 2.44e-01 | 0.0391 |
6383 | SDC2 | DCIS2 | Human | Breast | DCIS | 6.89e-48 | 2.91e-01 | 0.0085 |
6383 | SDC2 | AEH-subject1 | Human | Endometrium | AEH | 2.01e-14 | -4.25e-01 | -0.3059 |
6383 | SDC2 | AEH-subject2 | Human | Endometrium | AEH | 3.48e-18 | -5.08e-01 | -0.2525 |
6383 | SDC2 | AEH-subject3 | Human | Endometrium | AEH | 3.18e-23 | -5.11e-01 | -0.2576 |
6383 | SDC2 | AEH-subject4 | Human | Endometrium | AEH | 4.47e-09 | -2.99e-01 | -0.2657 |
6383 | SDC2 | AEH-subject5 | Human | Endometrium | AEH | 6.94e-10 | -3.34e-01 | -0.2953 |
6383 | SDC2 | EEC-subject1 | Human | Endometrium | EEC | 2.09e-21 | -5.23e-01 | -0.2682 |
6383 | SDC2 | EEC-subject2 | Human | Endometrium | EEC | 7.51e-24 | -5.08e-01 | -0.2607 |
6383 | SDC2 | EEC-subject3 | Human | Endometrium | EEC | 1.38e-46 | -5.92e-01 | -0.2525 |
6383 | SDC2 | EEC-subject4 | Human | Endometrium | EEC | 5.32e-12 | -4.02e-01 | -0.2571 |
6383 | SDC2 | EEC-subject5 | Human | Endometrium | EEC | 3.95e-29 | -5.94e-01 | -0.249 |
6383 | SDC2 | GSM5276934 | Human | Endometrium | EEC | 5.17e-11 | -2.71e-01 | -0.0913 |
6383 | SDC2 | GSM5276935 | Human | Endometrium | EEC | 1.81e-05 | -3.00e-01 | -0.123 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00507735 | Thyroid | PTC | regulation of dendrite development | 45/5968 | 103/18723 | 7.70e-03 | 3.27e-02 | 45 |
GO:001097523 | Thyroid | ATC | regulation of neuron projection development | 212/6293 | 445/18723 | 4.16e-10 | 1.14e-08 | 212 |
GO:0016358110 | Thyroid | ATC | dendrite development | 119/6293 | 243/18723 | 4.65e-07 | 6.75e-06 | 119 |
GO:004881315 | Thyroid | ATC | dendrite morphogenesis | 71/6293 | 146/18723 | 1.18e-04 | 8.38e-04 | 71 |
GO:005077312 | Thyroid | ATC | regulation of dendrite development | 46/6293 | 103/18723 | 1.26e-02 | 4.42e-02 | 46 |
Page: 1 2 3 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0541824 | Breast | IDC | Fluid shear stress and atherosclerosis | 34/867 | 139/8465 | 9.41e-07 | 1.61e-05 | 1.20e-05 | 34 |
hsa0520523 | Breast | IDC | Proteoglycans in cancer | 42/867 | 205/8465 | 7.69e-06 | 9.99e-05 | 7.48e-05 | 42 |
hsa0541834 | Breast | IDC | Fluid shear stress and atherosclerosis | 34/867 | 139/8465 | 9.41e-07 | 1.61e-05 | 1.20e-05 | 34 |
hsa0520533 | Breast | IDC | Proteoglycans in cancer | 42/867 | 205/8465 | 7.69e-06 | 9.99e-05 | 7.48e-05 | 42 |
hsa0541826 | Endometrium | AEH | Fluid shear stress and atherosclerosis | 43/1197 | 139/8465 | 2.47e-07 | 3.49e-06 | 2.55e-06 | 43 |
hsa0520518 | Endometrium | AEH | Proteoglycans in cancer | 53/1197 | 205/8465 | 5.43e-06 | 6.53e-05 | 4.78e-05 | 53 |
hsa05418112 | Endometrium | AEH | Fluid shear stress and atherosclerosis | 43/1197 | 139/8465 | 2.47e-07 | 3.49e-06 | 2.55e-06 | 43 |
hsa0520519 | Endometrium | AEH | Proteoglycans in cancer | 53/1197 | 205/8465 | 5.43e-06 | 6.53e-05 | 4.78e-05 | 53 |
hsa0541827 | Endometrium | EEC | Fluid shear stress and atherosclerosis | 45/1237 | 139/8465 | 7.76e-08 | 1.22e-06 | 9.07e-07 | 45 |
hsa0520524 | Endometrium | EEC | Proteoglycans in cancer | 52/1237 | 205/8465 | 3.01e-05 | 3.19e-04 | 2.38e-04 | 52 |
hsa0541836 | Endometrium | EEC | Fluid shear stress and atherosclerosis | 45/1237 | 139/8465 | 7.76e-08 | 1.22e-06 | 9.07e-07 | 45 |
hsa0520534 | Endometrium | EEC | Proteoglycans in cancer | 52/1237 | 205/8465 | 3.01e-05 | 3.19e-04 | 2.38e-04 | 52 |
hsa05418211 | Esophagus | ESCC | Fluid shear stress and atherosclerosis | 109/4205 | 139/8465 | 2.00e-12 | 3.72e-11 | 1.90e-11 | 109 |
hsa0520529 | Esophagus | ESCC | Proteoglycans in cancer | 138/4205 | 205/8465 | 1.79e-07 | 1.40e-06 | 7.15e-07 | 138 |
hsa05418310 | Esophagus | ESCC | Fluid shear stress and atherosclerosis | 109/4205 | 139/8465 | 2.00e-12 | 3.72e-11 | 1.90e-11 | 109 |
hsa0520537 | Esophagus | ESCC | Proteoglycans in cancer | 138/4205 | 205/8465 | 1.79e-07 | 1.40e-06 | 7.15e-07 | 138 |
hsa0541814 | Liver | NAFLD | Fluid shear stress and atherosclerosis | 30/1043 | 139/8465 | 1.37e-03 | 1.71e-02 | 1.38e-02 | 30 |
hsa0541815 | Liver | NAFLD | Fluid shear stress and atherosclerosis | 30/1043 | 139/8465 | 1.37e-03 | 1.71e-02 | 1.38e-02 | 30 |
hsa0541822 | Liver | Cirrhotic | Fluid shear stress and atherosclerosis | 62/2530 | 139/8465 | 1.53e-04 | 1.06e-03 | 6.54e-04 | 62 |
hsa0520510 | Liver | Cirrhotic | Proteoglycans in cancer | 85/2530 | 205/8465 | 2.37e-04 | 1.58e-03 | 9.75e-04 | 85 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
ANGPTL4 | SDC2 | ANGPTL4_SDC2 | ANGPTL | Breast | ADJ |
MDK | SDC2 | MDK_SDC2 | MK | Breast | ADJ |
MDK | SDC2 | MDK_SDC2 | MK | Breast | DCIS |
PTN | SDC2 | PTN_SDC2 | PTN | Breast | DCIS |
ANGPTL4 | SDC2 | ANGPTL4_SDC2 | ANGPTL | Breast | DCIS |
MDK | SDC2 | MDK_SDC2 | MK | Breast | Healthy |
ANGPTL4 | SDC2 | ANGPTL4_SDC2 | ANGPTL | Breast | Healthy |
PTN | SDC2 | PTN_SDC2 | PTN | Breast | Healthy |
MDK | SDC2 | MDK_SDC2 | MK | Breast | IDC |
ANGPTL4 | SDC2 | ANGPTL4_SDC2 | ANGPTL | Breast | IDC |
ANGPTL4 | SDC2 | ANGPTL4_SDC2 | ANGPTL | Breast | Precancer |
MDK | SDC2 | MDK_SDC2 | MK | Breast | Precancer |
MDK | SDC2 | MDK_SDC2 | MK | Cervix | ADJ |
PTN | SDC2 | PTN_SDC2 | PTN | Cervix | ADJ |
MDK | SDC2 | MDK_SDC2 | MK | Cervix | CC |
PTN | SDC2 | PTN_SDC2 | PTN | Cervix | CC |
ANGPTL4 | SDC2 | ANGPTL4_SDC2 | ANGPTL | Cervix | CC |
MDK | SDC2 | MDK_SDC2 | MK | Cervix | Healthy |
MDK | SDC2 | MDK_SDC2 | MK | Cervix | Precancer |
PTN | SDC2 | PTN_SDC2 | PTN | Cervix | Precancer |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SDC2 | SNV | Missense_Mutation | rs200028820 | c.373N>A | p.Glu125Lys | p.E125K | P34741 | protein_coding | tolerated(0.83) | benign(0.207) | TCGA-D8-A1XZ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen+anastrozolum | SD |
SDC2 | SNV | Missense_Mutation | c.144C>A | p.Asp48Glu | p.D48E | P34741 | protein_coding | tolerated(0.07) | probably_damaging(0.999) | TCGA-E9-A1R7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | fareston | SD | |
SDC2 | insertion | Frame_Shift_Ins | novel | c.583_584insATTTCATATT | p.Pro195HisfsTer6 | p.P195Hfs*6 | P34741 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
SDC2 | SNV | Missense_Mutation | rs200028820 | c.373N>A | p.Glu125Lys | p.E125K | P34741 | protein_coding | tolerated(0.83) | benign(0.207) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
SDC2 | SNV | Missense_Mutation | c.593A>G | p.Glu198Gly | p.E198G | P34741 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AZ-5403-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
SDC2 | SNV | Missense_Mutation | novel | c.26N>G | p.Thr9Ser | p.T9S | P34741 | protein_coding | tolerated(0.32) | benign(0.001) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
SDC2 | SNV | Missense_Mutation | rs774751152 | c.509N>A | p.Arg170His | p.R170H | P34741 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D5-6928-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
SDC2 | SNV | Missense_Mutation | c.479N>A | p.Ala160Glu | p.A160E | P34741 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AF-2690-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
SDC2 | SNV | Missense_Mutation | novel | c.472N>A | p.Leu158Ile | p.L158I | P34741 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
SDC2 | SNV | Missense_Mutation | rs774751152 | c.509N>A | p.Arg170His | p.R170H | P34741 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EI-6514-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Chemotherapy | 5-fu | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6383 | SDC2 | CELL SURFACE, DRUGGABLE GENOME | HEPARAN SULFATE | 8642635 |
Page: 1 |